logo-loader
viewANGLE PLC

ANGLE liquid biopsy beats the gold standard when it comes to identifying cells that are indicative of cancer spread

The work was carried out by researchers at Western University and Lawson Health Research Institute, Ontario, Canada

ANGLE PLC -

ANGLE PLC (LON:AGL, OTCQX:ANPCY) has shared research that shows its Parsortix liquid biopsy is able to identify a certain type of cancer cell that is indicative of the spread of the disease throughout the body – a process called metastasis.

It was also better in a head-to-head in this regard than the current antibody-based gold standard for isolating circulating tumour cells (CTC).

The two systems were on a par in identifying an epithelial breast cancer line; however, Parsortix harvested “significantly more” mesenchymal prostate CTCs than the traditional method.

Mesenchymal cells are indicative of metastases having undergone a change from the epithelial phenotype.

“Although the transition to a mesenchymal phenotype is associated with increased metastatic potential and worse prognosis, many CTC isolation methods, including the leading antibody-based system, only identify cells expressing epithelial markers,” ANGLE explained in a statement.

The work was carried out by researchers at Western University and Lawson Health Research Institute, Ontario, Canada.

Senior oncologist, Professor Alison Allan, said: "It is estimated that 90% of cancer-related deaths are due to metastatic disease because current therapies are non-curative against these aggressive cancers.

“Epithelial to mesenchymal transition (EMT) is well established as an important marker of metastasis, giving rise to cells with greater migratory capacity and invasiveness.

“However, many technologies used to detect CTCs rely on epithelial biomarkers. Here we demonstrate the unique attributes of Parsortix which position it as an ideal CTC platform for use in the clinic, including metastatic patients with predominantly mesenchymal CTCs."

Quick facts: ANGLE PLC

Price: 81.8 GBX

AIM:AGL
Market: AIM
Market Cap: £176.24 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE present at the Proactive One2One live virtual conference

ANGLE PLC's (LON:AGL) Andrew Newland (CEO) & Ian Griffiths (FD) pitch to investors at the Proactive One2One live virtual conference. ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor...

on 22/1/21

2 min read